Traps for the Unwary: The Impact of the False Claims Act on Start-Up and Venture-Stage Life Sciences Companies

By Karen Lovitch

A government investigation or enforcement action can disrupt a business, delay the launch of a new product, or threaten funding. Life sciences companies that participate in federal grant programs need to be aware of the risks associated with non-compliance with rules and regulations governing those programs. On November 20, 2013, Karen Lovitch, David Barmak, Kevin McGinty, and Scott Samuels of Mintz Levin will present a webinar to identify best practices for managing employees and fostering compliance in a growth company environment.

Click here to register for the webinar.

Subscribe To Viewpoints

Published

    • Viewpoint Topics

  • Health Care

    • Professionals

  • Karen Lovitch

    • Author

    Karen Lovitch

    Karen Lovitch

    Member / Chair, Health Law Practice & Chair, Health Care Enforcement Defense Practice

    Karen Lovitch is a Member at Mintz who advises industry clients on regulatory, transactional, operational, and enforcement matters. She has deep experience handling FCA investigations and qui tam litigation for laboratories and diagnostics companies.